Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002608-13-GB

Enrollment

Registered

2005-04-19

Start date

2005-05-16

Completion date

Unknown

Last updated

2019-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease with psychosis

Interventions

Trade Name: Seroquel Product Name: Seroquel Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Film-coated tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinically significant psychotic symptoms Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Identified treatable medical causes of psychosis; recent cerebrovascular disease; concurrent medications known to interact with quetiapine

Design outcomes

Primary

Measure	Time frame
Main Objective: To establish the efficacy of quetiapine in the treatment of psychosis in Parkinson's disease;Secondary Objective: To examine the adverse effects of quetiapine in this patient group;Primary end point(s): Psychosis symptoms score; time remaining in the trial	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026